Selenium moves insulin markers, not blood sugar

Diabetes and metabolic syndrome are closely tied to oxidative stress, inflammation and impaired insulin signalling, which is why micronutrients with antioxidant roles keep attracting attention as possible helpers. Selenium is an essential trace element with antioxidant and immune-modulating functions, and it has been proposed as an adjunctive strategy for metabolic regulation. The trouble is that randomised trials have returned inconsistent answers, with some suggesting benefit and others finding nothing. This review set out to establish what selenium supplementation actually does to blood sugar control, oxidative stress, lipids and related measures in adults, and to identify who, if anyone, stands to benefit.

The researchers searched nine databases, including PubMed, Embase, Cochrane CENTRAL and several Chinese databases, through 12 August 2025 for randomised controlled trials of oral selenium supplementation in adults, including pregnant women with gestational diabetes. Outcomes spanned fasting plasma glucose, glycated haemoglobin, fasting insulin, indices of insulin resistance and beta-cell function, oxidative stress and inflammatory biomarkers, lipids, and body and blood-pressure measures. Random-effects models pooled the results, and the team ran subgroup, dose-response and sensitivity analyses while rating the certainty of the evidence. In total, 52 treatment arms covering 10,916 participants were included.

Selenium supplementation reduced fasting insulin, HOMA-IR and HOMA-β and raised QUICKI, all markers connected to insulin sensitivity, yet fasting plasma glucose and glycated haemoglobin showed no clear overall effect. Antioxidant and inflammatory markers improved: glutathione, total antioxidant capacity, superoxide dismutase, glutathione peroxidase and serum selenium rose, while malondialdehyde and high-sensitivity C-reactive protein fell, with nitric oxide unchanged. Lipids shifted modestly, with higher HDL cholesterol and lower LDL, triglycerides and total cholesterol. Among body and blood-pressure outcomes, only diastolic blood pressure was reduced. Effects varied by dose, duration, participant characteristics and the selenium exposure of the region studied.

Earlier trials of selenium were inconsistent, and this pooling helps explain why: the effects appear to depend on dose, duration and, crucially, how much selenium people had to begin with. The authors argue the findings are most applicable to populations with marginal or low baseline selenium status and should be extrapolated cautiously to settings where people are already replete. The gap between improved insulin-sensitivity markers and unmoved glucose and glycated haemoglobin remains an open question. The review calls for long-term, high-quality trials to pin down baseline-specific effects, safe dose ranges and long-term safety.

If you eat a varied diet in a region where selenium intake is adequate, this review offers little reason to expect a supplement to improve your blood sugar, since the measures that define glycaemic control did not clearly move. For people whose selenium intake is genuinely marginal, the improvements across insulin-sensitivity, antioxidant and lipid markers are a reason to think baseline status matters. Everything that shifted here is an intermediate marker rather than a disease outcome, so this is useful background rather than a green light, and the safe upper range of dosing is still being worked out.